Henry Schein, Inc. $HSIC Stake Boosted by Gateway Investment Advisers LLC

Gateway Investment Advisers LLC lifted its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 214.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,091 shares of the company’s stock after purchasing an additional 8,243 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Henry Schein were worth $1,010,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Ameriprise Financial Inc. boosted its position in Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after purchasing an additional 2,199,695 shares during the period. Bank of Montreal Can increased its position in Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock worth $162,102,000 after buying an additional 2,087,666 shares during the period. Norges Bank acquired a new stake in Henry Schein in the fourth quarter worth $88,116,000. Southpoint Capital Advisors LP lifted its stake in Henry Schein by 28.0% in the first quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock valued at $235,840,000 after buying an additional 700,000 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in Henry Schein by 204.2% in the second quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of HSIC opened at $90.74 on Thursday. Henry Schein, Inc. has a one year low of $61.94 and a one year high of $92.18. The stock’s fifty day moving average is $84.28 and its 200-day moving average is $78.89. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.73 and a current ratio of 1.32. The firm has a market capitalization of $10.11 billion, a price-to-earnings ratio of 26.45, a price-to-earnings-growth ratio of 1.70 and a beta of 0.80.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.27 earnings per share for the quarter, topping the consensus estimate of $1.24 by $0.03. The business had revenue of $3.46 billion during the quarter, compared to the consensus estimate of $3.37 billion. Henry Schein had a net margin of 2.96% and a return on equity of 15.97%. The company’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.10 earnings per share. Henry Schein has set its FY 2026 guidance at 5.290-5.390 EPS. Equities analysts anticipate that Henry Schein, Inc. will post 5.35 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a research report on Friday, July 31st. Wall Street Zen lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Sunday. Morgan Stanley restated an “underweight” rating and issued a $64.00 target price (up from $61.00) on shares of Henry Schein in a research report on Friday, April 24th. Stifel Nicolaus set a $95.00 price target on shares of Henry Schein in a research note on Wednesday, August 5th. Finally, Mizuho cut their price target on Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Henry Schein has a consensus rating of “Hold” and a consensus price target of $92.27.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.